Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Investigator: Eric Bernicker, MD

Study Coordinator: Meena Medepalli

Status: Enrolling

ClinicalTrials.gov Number: NCT02193282

Phone: 713.441.4203

IRB Number: Pro00012699

Description

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
More to Explore